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Abstract Diffuse intrinsic pontine glioma (DIPG) is a rare 
and deadly childhood malignancy. After 40 years of mostly 
single-center, often non-randomized trials with variable 
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patient inclusions, there has been no improvement in sur-
vival. It is therefore time for international collaboration in 
DIPG research, to provide new hope for children, parents and 
medical professionals fighting DIPG. In a first step towards 
collaboration, in 2011, a network of biologists and clini-
cians working in the field of DIPG was established within 
the European Society for Paediatric Oncology (SIOPE) 
Brain Tumour Group: the SIOPE DIPG Network. By bring-
ing together biomedical professionals and parents as patient 
representatives, several collaborative DIPG-related projects 
have been realized. With help from experts in the fields of 
information technology, and legal advisors, an international, 
web-based comprehensive database was developed, The 
SIOPE DIPG Registry and Imaging Repository, to centrally 
collect data of DIPG patients. As for April 2016, clinical 
data as well as MR-scans of 694 patients have been entered 
into the SIOPE DIPG Registry/Imaging Repository. The 
median progression free survival is 6.0 months (95% Confi-
dence Interval (CI) 5.6–6.4 months) and the median overall 
survival is 11.0 months (95% CI 10.5–11.5 months). At two 
and five years post-diagnosis, 10 and 2% of patients are alive, 
respectively. The establishment of the SIOPE DIPG Network 
and SIOPE DIPG Registry means a paradigm shift towards 
collaborative research into DIPG. This is seen as an essential 
first step towards understanding the disease, improving care 
and (ultimately) cure for children with DIPG.
Keywords Diffuse intrinsic pontine glioma (DIPG) · 
Collaboration · International research-infrastructure · 
SIOPE DIPG network · SIOPE DIPG registry
Introduction
Diffuse intrinsic pontine glioma (DIPG) is a pediatric 
brain cancer for which there is no curative treatment yet. 
Despite multiple clinical trials studying (combinations 
of) cytotoxic chemotherapy, including novel agents, the 
median overall survival of 9  months has not improved 
over the past decades [1, 2]. Although major advances 
have been accomplished in knowledge on the biological 
background of the disease by discovery of a high preva-
lence of specific mutations in genes encoding for histone 
3.1 and 3.3, ACVR1 and P53 [3–9], much is yet to be 
learned on the mechanisms that contribute to treatment 
resistance. Research on the DIPG patient population, 
however, is hampered because integrative, large scale 
clinical, radiological and biological data are lacking.
There are several factors that contribute to the scar-
city of data. First, DIPG is an orphan disease with a 
yearly incidence of 2.32 per 1,000,000 residents aged 
0–20 years [10]. Second, DIPGs are diagnosed clini-
cally, based on typical MR-imaging findings [11], in 
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combination with a classic triad of neurological symp-
toms [12]. Biopsy procedures to obtain tumor material 
have long been considered dangerous and not contrib-
uting to the diagnosis, treatment approach or survival 
outcome [13]. Fortunately, recent years have seen an 
emergence of studies that include biopsies, however, the 
discovery of new mutations have caused an on-going 
debate about the actual definition of the disease itself [9, 
14]. This is exemplified by the recently published new 
WHO classification of central nervous system tumors, 
that has reclassified DIPG to the category of WHO grade 
IV diffuse midline gliomas with histone mutations [15]. 
Inconsistent definition of DIPG has hampered in- and 
exclusion or response criteria for clinical trials, which 
resulted in a great variety of mostly incomparable clini-
cal trials, many of which are single-center, single-arm 
studies with only few patients enrolled [10].
Collaboration and data sharing are promising strate-
gies for tackling rare diseases, by facilitating uniform 
and hypothesis-driven research [16]. To overcome the 
current lack of data and improve the integration, speed, 
quality, and coherence of research, we aimed to (1) cre-
ate a DIPG research-infrastructure consortium, and (2) 
initiate collaborative collection of comprehensive data 
on DIPG patients. This paper describes the methodology 
of the set-up of an international research network infra-
structure, the SIOPE DIPG Network and SIOPE DIPG 
Registry, including legal and IT aspects, as well as pre-
liminary patient inclusion data.
Materials and methods
The establishment of a research‑infrastructure 
consortium
In January 2011, in a DIPG meeting organized by the 
Semmy Foundation in Amsterdam, the SIOPE DIPG 
Network was established as a sub-committee of the 
high-grade glioma (HGG) working group of Interna-
tional Society of Paediatric Oncology Europe (SIOPE). 
The SIOPE DIPG Network is a collaboration of pediat-
ric oncologists, neurologists, neurosurgeons, radiothera-
pists, radiologists, pathologists, molecular biologists, 
psychologists and others motivated to carry out excellent 
clinical and biological research in the field of DIPG. Ini-
tially started as a European network, it has extended to 
colleagues from all over the world, with participants from 
Russia, Turkey and Mexico.
The SIOPE DIPG Network is comprised of (i) an 
executive committee, (ii) a group of scientific advisors, 
(iii) National Coordinators (NCs) and (iv) members. The 
Executive Committee (i) manages and controls the DIPG 
Network, and abides by and enforces the mission and the 
core values of the Network. Scientific Advisors (ii) are 
individuals with expertise in areas such as: biostatistics 
and biometry, medical ethics and health policy, basic sci-
ence research, translational research, (neuro)psychology, 
neuroimaging, or other areas not mentioned. Scientific 
Advisors are consulted to advise the Executive Committee 
in matters of development and implementation of research 
protocols including ideas for innovative studies that could 
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be executed using the Network. NCs (iii) are those DIPG 
Network members that coordinate collaboration between 
the SIOPE DIPG Network and biologists and clinicians in 
their countries. NCs identify and select hospitals and scien-
tific experts in their countries, that are involved in the treat-
ment of DIPG patients and that potentially may join the 
DIPG Network. DIPG Network members (iv) participate 
in research projects initiated by the DIPG Network fol-
lowing the principles of Good Clinical Practice. Potential 
members need to be approved by the Executive Committee 
before subscription to the DIPG Network. Network mem-
bers are free to decide on whether they wish to participate 
in a research project on a case-by-case basis and at their 
sole discretion.
The mission of the SIOPE DIPG Network is to serve as 
a research-infrastructure for the design and execution of 
high quality, international multicenter laboratory and clini-
cal studies, intended to enhance the understanding of DIPG 
and to improve outcome of patients suffering from DIPG. 
The mission, aims, core values and structure of the SIOPE 
DIPG Network are described in the SIOPE DIPG Network 
Bylaws (see Legal aspects).
Collaborative collection of comprehensive data
The establishment of a DIPG registry was set as first pro-
ject of the Network, with the purpose to include clini-
cal, biological and centrally reviewed radiology data of 
patients with DIPG, both in- and outside clinical trials. 
The SIOPE DIPG Registry is composed of an online web 
application and database for clinical data, and an Imaging 
Repository for radiological data (Fig. 1).
In parallel, an International DIPG Registry was initiated 
and developed, which includes patient data from the USA, 
Canada, Australia and New Zealand. To allow for the inclu-
sion of uniform data, standardized electronic Case Report 
Forms (e-CRFs; Fig.  2) were developed by the SIOPE 
DIPG Network, in coordination with colleagues from the 
International DIPG Registry. The online e-CRFs collect 
Fig. 1  Organizational chart of the SIOPE DIPG registry and imaging 
repository. For details on the quality control process please see Sup-
plementary Fig. 1
Fig. 2  Screenshot of the SIOPE 
DIPG Registry showing the 
electronic case report forms 
(e-CRFs). The open tab repre-
sents the e-CRF for history and 
physical exam
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data on demographics, medical history and physical exam 
at time of diagnosis together with the results from radio-
logical and pathological review by the local hospital, treat-
ment data (including radiotherapy, chemotherapy, surgery 
and supportive care such as steroids), data on clinical and 
radiological follow up, and last known status of the patient 
(see Data Entry Manual; Supplementary material 1).
In parallel to the clinical data, anonymized MRI-scans 
scans are uploaded via a secure FTP server or sent on 
CDs. De-identification/ pseudonymization, according 
to the country’s law, is performed either in the referring 
center, during upload or at the time of receipt. When fully 
anonymized, these images are uploaded into the SIOPE 
DIPG Imaging Repository (Fig.  1). Expert neuroradiolo-
gists are brought together in a central neuroradiology panel. 
This panel has access to view assigned images from the 
Imaging Repository for blinded central review of submitted 
cases.
Eligibility criteria
The criteria for patient inclusion in the SIOPE DIPG Reg-
istry are: (i) patients with DIPG, or with focal Pontine 
Glioma (fPG), defined as a T1-weighted hypointense and 
T2-weighted hyperintense tumor with at least 50% involve-
ment of the pons (DIPG) or less than 50% involvement of 
the pons (fPG) on T2, and as confirmed by expert neuro-
radiologists via the central radiology review procedure 
described above (ii) age at diagnosis between 0 and 21 
years, and (iii) written informed consent in case of pro-
spective registration. Furthermore, in order to enable vali-
dation of the diagnosis following the current guideline, a 
minimum of diagnostic criteria is required i.e. clinical and 
radiological data (MRI scans) to be shared in the registry 
and, if available, pathology data.
Ethical considerations
The SIOPE DIPG Registry is conducted according to the 
principles of the Declaration of Helsinki. No personal iden-
tifiers, besides date of birth, are included in the e-CRFs. 
If in a certain country this is not allowed, age at diagno-
sis is submitted instead. All patients are assigned a unique 
SIOPE DIPG Registry number. Per member site, a separate 
list, kept under a special password, connects the DIPG Reg-
istry number with the personal identifiers. Access to this 
list is restricted to a local coordinator at each site.
In most participating countries informed consent is 
not mandatory for retrospective registration of (mostly 
deceased) patients. If required a consent form is sent to par-
ents and signed. Prospective registration of living patients 
requires an informed consent procedure. National coordina-
tors are responsible for the translation of the standardized 
informed consent to the language of their country. Trans-
lated forms will be centrally collected and available to local 
hospitals upon request. In this procedure, a SIOPE Network 
member informs parents (and patients), after which he/she 
provides the Patient Information Form (Supplementary 
material 2) and requests for informed consent. Parents or 
patients may reject participation at all times.
Data collection
Each country represented in the SIOPE DIPG Network is 
committed to delivering data to the SIOPE DIPG Regis-
try and Imaging Repository. After subscription to the Net-
work, the approved Network member receives a username 
and password to enter data into the Registry. Data collec-
tion covers both retrospective and prospective registration. 
Retrospective data will be collected from local hospitals, 
national registries and clinical trials. For prospective reg-
istration, Network members are encouraged to inform their 
patients about the existence of the SIOPE DIPG Registry 
followed by the informed consent procedure. In case of 
decline, the e-CRFs will be left blank, but a unique Reg-
istry number is created, which will only be used for epi-
demiologic studies. To describe data retrieval, as well as 
responsibility and ownership of the data, uniform interna-
tional agreements for collaborative research purposes were 
created (see Legal aspects).
Exhaustivity check and quality control of the data
To ensure the reliability, validity, and completeness of the 
data [17], an appropriate program of Quality Control was 
implemented (Supplementary Fig.  1). Quality Control of 
data is an integral part of the project and takes place at all 
stages: before, during and after data entry.
Data storage and safety
Based on the e-CRF’s, an optimized relational database 
was constructed. The database along with the web applica-
tion is hosted on a dedicated server where the web appli-
cation is the single point of contact with the database. All 
end-user connections use the secure HTTP (HTTPS) proto-
col to ensure protection of the privacy and integrity of the 
exchanged data. The server is placed within a Virtual Pri-
vate LAN protected by a dedicated firewall ring. For server 
maintenance purposes direct access to the server is only 
possible through a restricted virtual private network (VPN) 
connection. The DIPG Registry is built on a generic frame-
work in which presentation, logic and data layer are sepa-
rated. The framework was designed with several active pro-
tection features to prevent unsolicited use of the application 
such as user/role/session validation, the use of antiforgery 
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tokens and brute force protection. To ensure data safety, 
database input controls and extensive audit trailing are 
used. Every action within the system and the database is 
logged. The server, application and database are moni-
tored 24h/7days and backups are made and stored daily 
on a different server in order to provide a disaster recov-
ery scenario. The SIOPE DIPG Registry framework here-
with provides a stable, secure and generic basis in any of its 
products. A penetration test (black box approach) was per-
formed to validate the effectiveness of the (visible) security 
implemented on the SIOPE DIPG Registry and Imaging 
Repository. This test will be repeated on a regular basis.
Legal aspects
The daily and financial management, and hosting of the 
SIOPE DIPG Registry is carried out by the Dutch Child-
hood Oncology Group (DCOG), a National Paediatric Hae-
matology-Oncology Society (NaPHOS) member of SIOPE. 
DCOG is mandated by the Executive Committee of the 
DIPG Network to act as a legal entity on its behalf in mat-
ters concerning the DIPG Registry, by a letter of mandate.
The construction of a collaborative research infra-
structure, with geographical differences in health care 
structures and legislation faces considerable challenges. 
Experts in the field of sensitive data transfer and access 
rights have been consulted to certify issues concern-
ing data anonymization, -collection, and -safety. To 
meet multinational standards, two legal documents have 
been drafted, abiding to EU law and taking into account 
SIOPE DIPG Network members’ national laws. The 
first contains the SIOPE DIPG Network Bylaws (Sup-
plementary material 3), that describe the mission, aims, 
core values and structure of the SIOPE DIPG Network 
as well as terms and conditions for submitting, review-
ing and approving proposals for research projects using 
data from the SIOPE DIPG Registry. Furthermore, the 
Bylaws provide a Scientific Advisory Agreement for con-
sultation of experts outside the SIOPE DIPG Network, 
such as specialised neuroradiologist for central radiology 
review. Second is the SIOPE DIPG Registry and Imaging 
Repository Regulatory Document (Supplementary mate-
rial 4), describing the terms and conditions for manage-
ment, maintenance of and access to the DIPG Registry 
and Imaging Repository.
Use of data
For strategic decisions concerning novel collaborative 
clinical and biological research projects in the field of 
DIPG, NCs meet or consult several times a year. In this 
way the SIOPE DIPG Network itself is responsible for 
the optimal use of obtained data. Data from the SIOPE 
DIPG Registry and Imaging Repository are available to 
researchers for collaborative, interdisciplinary, and trans-
lational studies. For use of the data from the Registry, the 
researcher must be a member of the SIOPE DIPG Net-
work. The availability of data to the researcher is condi-
tional to obtained approval from the Executive Commit-
tee, after submission of a project proposal, and permits 
and licenses required by the researcher’s national law. 
The Executive Committee may set additional conditions 
to a specific project and stipulates the general terms and 
conditions with regard to receipt and use of data. Subse-
quently, only requested, relevant data are selected from 
the DIPG Registry and made available to the researcher. 
The researcher owns results of a research project, includ-
ing the intellectual property rights thereto. Publication of 
results generated with data from the SIOPE DIPG Regis-
try requires to comply with rules concerning authorship, 
as defined by the International Committee of Medical 
Journal Editors (ICMJE). Each year, the Executive Com-
mittee sends a report to the members of the SIOPE DIPG 
Network on the number of approved, performed and 
rejected projects.
Results
International collaboration in DIPG research
Since its inception in 2011, the SIOPE DIPG Network has 
expanded each year. Currently, 27 countries (Austria, Bel-
gium, Croatia, Czech Republic, Denmark, Finland, France, 
Germany, Greece, Hungary, Iceland, Ireland, Italy, Lithu-
ania, Norway, Poland, Portugal, Slovakia, Slovenia, Spain, 
Sweden, Switzerland, The Netherlands, United Kingdom, 
Turkey, Russia, and Mexico; Supplementary Fig.  2) have 
committed to the SIOPE DIPG Network and Registry. 
There is also a close collaboration with the International 
DIPG Registry, which represents the collaborative efforts 
of physicians and researchers from North America, Can-
ada, Australia and New Zealand (Supplementary Fig.  2). 
To coordinate similar data collection, there are frequent 
telephone conferences and annual working visits between 
the SIOPE DIPG Network chair, the SIOPE DIPG Regis-
try coordinator and International DIPG Registry team sta-
tioned at the Clinical Management and Research Support 
Core (CMRSC) at Cincinnati Children’s Hospital Medical 
Center. Both DIPG registries are financially supported by 
The DIPG Collaborative, a collection of more than 20 par-
ent foundations with the common interest of promoting and 
funding research into DIPG.
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SIOPE DIPG registry and imaging repository
Currently, as a prerequisite to start prospective patient 
inclusion in the SIOPE DIPG Registry, members of the 
SIOPE DIPG Network are in the process of Medical Ethical 
Committee and IRB review, with some countries already 
including patient data upon approval. As of April 2016, 
six countries have submitted retrospective data of 694 
patients to the SIOPE DIPG Registry and Imaging Reposi-
tory. Data were retrieved from three national registries, two 
local hospitals, and one clinical trial. Figure  3 shows the 
age distribution of patients included in the SIOPE DIPG 
Registry, with a median age of 7 years (standard deviation 
(SD) ± 3.5). Table 1 shows the patient characteristics, clini-
cal, radiological and biological disease characteristics, and 
treatment details of the total cohort. For 94 patients, tumor 
material was available for genetic analysis. Results are 
shown in Table  2. The median progression free survival, 
defined as time from diagnosis to clinical signs of disease 
progression (i.e., increase of symptoms or new symptoms) 
and/or radiological tumor progression on MRI, was 6.0 
months (95% Confidence Interval (CI) 5.6–6.4 months). 
The median OS, defined as time from diagnosis to death, 
was 11.0 months (95% CI 10.5–11.5 months). PFS and OS 
are both plotted in Fig. 4a. Figure 4b, c show the PFS and 
OS stratified by mutational status. Figure 4d, finally, shows 
the distribution of time from progression to death (median 
4 months). Ten percent of patients were alive at 2  years 
post diagnosis. At 5 years post diagnosis only two percent 
were alive. No disease-free survival was observed.
Discussion
A first step is made to improve the infrastructure of research 
into DIPG. This was done by (1) the establishment of the 
SIOPE DIPG Network, and (2) the development and initia-
tion of the SIOPE DIPG Registry and Imaging Repository. 
This initiative, enabling collaborative research, is seen as 
major first step towards improving care and (ultimately) 
cure for children with DIPG.
Collaboration is pursued to overcome the factors ham-
pering research into DIPG. This paper is the first to publish 
pooled patient data of almost 700 DIPG patients collected 
from national registries, local hospitals and clinical trials. 
To date, published patient data are largely from phase I/
II trials, which cover only a small percentage of the actual 
population diagnosed with DIPG. This possibly results in 
publication/selection bias. Future registration of all DIPG 
patients, both in- and outside trials, will give the oppor-
tunity to analyze ‘real-life’ DIPG patient data resulting in 
better description of incidence, characteristics and survival 
of DIPG patients. Also, it will generate a representative 
reference cohort, which may be used as historical control 
in any future study. With the SIOPE DIPG Network and 
SIOPE DIPG Registry/Imaging Repository, an infrastruc-
ture has been created that allows for research transparency, 
international collaboration and the elimination of duplica-
tion of research efforts. Already two international studies 
were published by the SIOPE DIPG Network, concerning 
palliative care and end-of-life decisions [18] and steroid use 
[19] in DIPG patients. The first large-scale international 
study including all patients registered in the SIOPE DIPG 
Registry and International Registry, with an estimated total 
of >1000 DIPG cases, is currently being conducted. This 
study will evaluate the characteristics of long-term surviv-
ing patients in comparison to the total group of patients.
The preliminary patient data of the 694 patients cur-
rently included in the SIOPE DIPG Registry, shows an 
equal gender distribution, rapid onset of symptoms pre-
diagnosis (86% <12 weeks of which 66% within 6 weeks), 
a clinical presentation including cranial nerve palsy in 
the majority (85%) of patients, and two-third of patients 
showing gadolinium contrast enhancement on the diagnos-
tic MRI, of which 57% (39% of the total cohort) showed 
partial ring-like enhancement suggestive for necrosis. At 
time of diagnosis, only 1% of the diagnostic MRIs showed 
metastasis in the brain, and 2% in the spine. Eighteen per-
cent of patients present with hydrocephalus. Biopsy was 
performed in one-third of the patients, showing a range of 
WHO grades. From the 94 patients in whom histone muta-
tional status was determined, two-third harbored a H3F3A 
mutation, versus 21% of patients harboring a H1H3B muta-
tion, and 16 % were classified as wild-type. This distribu-
tion, as well as the observed difference in survival in favor 
Fig. 3  Histogram showing the age distribution of the total cohort
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Table 1  Demographics, disease 
characteristics and treatment 
data of the total cohort (n = 694)
Category Variable n Valid 
(%)
Total 694
Country Germany 312/694 45
Netherlands 132/694 19
France 118/694 17
Italy 79/694 11
United Kingdom 45/694 7
Croatia 8/694 1
Gender Female 359/694 52
Male 335/694 48
Age (mean, SD) 7.7 ± 3.5
Symptom duration <6 weeks 413/627 66
6–12 weeks 127/627 20
13–24 weeks 47/627 8
>24 weeks 40/627 6
Cranial nerve palsy Yes 484/568 85
No 84/568 15
Pyramidal signs Yes 270/562 48
No 292/562 52
Cerebellar signs Yes 338/562 60
No 224/562 40
T1-weighted Hypo-intense 422/439 96
Iso-intense 16/439 4
Hyper-intense 1/439 0
T2-weighted Hypo-intense 5/465 1
Iso-intense 2/465 0
Hyper-intense 458/465 99
Pontine involvement <50% 3/550 0
>50% 547/550 100
Tumor size Anterior-posterior Ø in mm (mean, SD) 36 ±7
Transverse Ø in mm (mean, SD) 43 ±8
Cranial-caudal Ø in mm (mean, SD) 42 ±9
Enhancement Yes 336/516 65
No 180/516 35
Ring-enhancement Yes 191/491 39
No 300/491 61
Margin Ill-defined 363/481 76
Well-defined 118/481 24
Extension Yes 493/549 90
No 56/549 10
Metastasis brain Yes 7/547 1
No 540/547 99
Metastasis spine Yes 8/420 2
No 412/420 98
Hemorrhage Yes 60/458 13
No 398/458 87
Necrosis Yes 191/473 40
No 282/473 60
Hydrocephalus Yes 89/505 18
No 416/505 82
Radiation Yes 650/691 94
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of the H1H3B mutational subgroup, is in line with interna-
tional literature [4, 6, 9, 20]. Almost all patients received 
radiotherapy, 9% received re-irradiation, and a sticking 
72% received chemotherapy, which is contradictory since 
there is no chemotherapeutic strategy yet, that has shown 
to be effective [1, 2]. Autopsy was performed in only 4% 
SD Standard Deviation, AP Anterior-posterior, WHO World Health Organization, *Following the 2016 
WHO classification criteria [15]
Table 1  (continued) Category Variable n Valid 
(%)
No 41/691 6
Chemotherapy at diagnosis Yes 498/689 72
*Oral 252/495 51
*IV 230/495 46
*Both 13/495 3
*Cytotoxic 323/495 65
*Targeted 129/495 26
*Both 43/495 9
*EGFR 111/495 22
*mTOR / PI3K 15/495 3
*EGFR/mTOR 1/495 0
*HDAC inhibitor 37/495 8
*Other 331/495 67
No 191/689 28
Chemotherapy at progressive disease Yes 370/684 54
No 314/684 46
Re-irradiation Yes 61/694 9
No 633/694 91
Hydrocephalus treatment Yes 158/694 23
No 536/694 77
Biopsy Yes 260/694 37
*WHO Grade IV 91/260 35
*Glioblastoma multiforme 76/91 84
*DIPG^ 15/91 16
*WHO Grade III 71/260 27
*Anaplastic astrocytoma 61/71 86
*Anaplastic oligoastrocytoma 8/71 11
*Anaplastic oligodendroglioma 2/71 3
*WHO Grade II 38/260 15
*Diffuse astrocytoma 20/38 53
*Low-grade astrocytoma n.o.s 11/38 29
*Fibrillary astrocytoma 4/38 10
*Oligoastrocytoma 2/38 5
*Oligodendroglioma 1/38 3
*WHO Grade unknown 60/260 23
No 434/694 63
Autopsy Yes 16/380 4
*WHO Grade IV 12/16 75
*Glioblastoma multiforme 12/12 100
*WHO Grade II-IV 1/16 6
*Astrocytoma 1/1 100
*WHO Grade unknown 3/16 19
No 364/380 96
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of patients. Currently, the majority of patients included in 
the SIOPE DIPG Registry are patients with a radiologically 
confirmed and centrally reviewed T1-weighted hypointense 
and T2-weighted hyperintense tumor with at least 50% 
involvement of the pons (DIPG) [11]. The recent WHO 
re-classification, however, may imply that the inclusion cri-
teria for the SIOPE DIPG Registry need to be adjusted to 
also include patients with non-pontine diffuse midline glio-
mas in the future.
Dependent on the extent to which biopsies and autopsies 
will be (re-)introduced for DIPG, data on biological char-
acteristics will gradually increment in the Registry, which 
will increase the knowledge on DIPG etiology, pathogen-
esis, possible drug targets and the mechanisms that con-
tribute to the observed resistance to treatment. Further-
more, big-data analysis of aggregated clinical, radiological 
and especially biological data facilitates the discovery of 
patterns that indicate patient subgroups, which enables 
consensus formation on classification, in-/exclusion and 
response criteria, and improves the quality and compara-
bility of future trials. Moreover, joining forces within an 
international research-infrastructure will stimulate the initi-
ation of, and active accrual in, international multicenter tri-
als, with sufficient power to address the many unanswered 
research questions. This, together with the recent evolution 
of ideas concerning therapeutic strategies [21–24], should 
facilitate the identification and selection of novel tolerable 
and effective therapies.
Data collection in the Registry will have some (initial) 
limitations. Due to the former lack of local hospital- and 
national registrations, lack of specific ICD-codes1, and due 
to a presumed limited documentation of clinical, radiologi-
cal and pathological data, retrospective data collection will 
very likely be incomplete. Based on data from the Dutch 
retrospective study [10], and included parties in the SIOPE 
DIPG Network (with a total number of about 600 million 
residents aged 0–19 years; April 2016) it is estimated that 
over 350 children are eligible for prospective registration in 
the SIOPE DIPG Registry each year. It is expected that 
annually about 200 patients (60%) will be registered in the 
first years, and that this number will increase when the 
SIOPE DIPG Network expands, resulting in higher data 
completeness per country over time.
Recent publications in DIPG literature have shown that 
coupling genetic data to clinical data will become increas-
ingly important to understand and/or predict the clinical 
behavior of the disease [9, 14]. Therefore, as for now, data 
of the most common genetic aberrations are entered in the 
Registry via a ‘Biopsy/Autopsy e-CRF’. A next step of the 
SIOPE DIPG Registry is to establish a (virtual) biobank of 
DIPG material, linked with the DIPG Genomics Reposi-
tory at Progenetix (dipg.progenetix.org), a cancer genome 
database [25]. Ideally, the increased availability of DIPG 
tumor tissue will lead to generally available, representa-
tive, and possibly even patient subgroup-specific cell cul-
tures and xenograft models, which enable thorough basic 
research and high-throughput screening of candidate thera-
pies. Other future perspectives are to include questionnaires 
for Quality of Life research since research on this important 
subject is largely lacking, especially data on end-stage dis-
ease symptoms and the associated specific needs for pal-
liative and end-of-life care [18]. The collection of conven-
tional MR-imaging data in the Imaging Repository, will in 
the future be expanded to multimodality MR-imaging and 
other advanced imaging techniques such as PET. The data 
also might be useful for educational purposes (e-learning) 
in an aim to improve diagnostics of these tumors.
To conclude, with the collaborative efforts of profes-
sionals treating children with DIPG, patient/parent organi-
zations, legal advisors, experts in the field of informa-
tion technology and imaging experts, an international 
research-infrastructure was successfully set up, which led 
to the development and initiation of the SIOPE DIPG Reg-
istry. With already 694 patients registered, this Registry 
stimulates collaborative preclinical and clinical research 
efforts. The first study using data from both the SIOPE 
1  World Health Organisation (WHO) International Classification of 
Diseases (ICD).
Table 2  Genetic characteristics of patients with available tumor 
material (n = 94)
Category Variable n VALID %
Total 94
Material type Biopsy 86/94 92
Autopsy 8/94 8
Histone mutations H3F3A 59/94 63
H1H3B 20/94 21
H1H3C 0/16 –
H1H3I 0/16 –
Wild-type 15/94 16
Additional mutations ACVR1 9/45 17
Wild-type 45/54 83
TP53 18/29 62
Wild-type 11/29 38
ATM 3/16 19
Wild-type 13/16 81
PIK3CA 5/30 17
Wild-type 25/30 83
PIK3R1 3/15 20
Wild-type 12/15 80
MET 1/15 7
Wild-type 14/15 93
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and International Registry is already in its final stages. The 
existence of the International DIPG Registry, surveying 
similar data as the SIOPE DIPG Registry, allows for exter-
nal cross-validation of data, generating robust data on the 
DIPG patient population. Big data analysis of the Regis-
try’s data will potentially lead to the discovery of patterns 
that pave the way to the identification of effective therapies 
towards a cure for patients suffering from DIPG.
The methodology used for the SIOPE DIPG Registry 
will, most likely, be easily translatable to other pediatric 
cancer registries, as almost all of these are orphan diseases 
that could benefit from international registration and col-
laboration in research.
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